Atyr PHARMA (NASDAQ:ATYR) Earns “Buy” Rating from HC Wainwright
HC Wainwright reissued their buy rating on shares of Atyr PHARMA (NASDAQ:ATYR – Free Report) in a research note published on Friday morning,Benzinga reports. They currently have a $35.00 price objective on the stock. A number of other research firms have also issued reports on ATYR. Leerink Partners began coverage on Atyr PHARMA in a […]
HC Wainwright reissued their buy rating on shares of Atyr PHARMA (NASDAQ:ATYR – Free Report) in a research note published on Friday morning,Benzinga reports. They currently have a $35.00 price objective on the stock. A number of other research firms have also issued reports on ATYR. Leerink Partners began coverage on Atyr PHARMA in a […]
